Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00708773
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Irinotecan — DRUG
    90 minute IV infusion once every 3 weeks. Dose will be based on sex and genotype determination.

Study Details

Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.

Key Dates

First listed
Jul 2, 2008
Start date
Feb 28, 2006
Status verified
Jan 2017
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016

Study Design

Enrollment
68 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm

Primary Outcome Measure

maximum tolerated dose [ Time Frame: 3 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637-
NorthShore University HealthSystemEvanstonIllinois60201-

Find similar trials in Chicago, IL

By research site
University of Chicago· Chicago, ILNorthShore University HealthSystem· Evanston, IL

Related Studies